| ISIN | CH1106275089 |
|---|---|
| Valor Number | 110627508 |
| Bloomberg Global ID | |
| Fund Name | Swiss Excellence I (CHF) |
| Fund Provider |
NS Partners SA
Phone: +41 22 906 52 50 E-Mail: reporting@nspgroup.com |
| Fund Provider | NS Partners SA |
| Representative in Switzerland | |
| Distributor(s) |
Banque Cantonale Vaudoise Lausanne Phone: +41 21 212 10 00 |
| Asset Class | Equities |
| EFC Category | |
| Distribution Policy | Distribution |
| Home Country | Switzerland |
| Issuing Condition | The fund does not charge any issuing commission and/or fees (units are issued at the NAV) |
| Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
| Investment Strategy *** | Swiss Excellence pursues the objective of outperforming the Swiss equity market as measured by the Swiss Leader Index® (SLI) Total Return. For the Sub-fund's main investment category, the asset manager integrates environmental, social, and governance (ESG) criteria into the stock selection process and towards the weighting of companies in the portfolio. The Sub-fund invests the majority of its assets into equities and security rights of companies having their registered office either located in Switzerland or carrying out a significant amount of their economic activity in Switzerland. Pensofinance SA, serving as an advisor, provides the asset manager with qualitative analyses of Swiss companies. |
| Peculiarities |
| Current Price * | 120.17 CHF | 30.10.2025 |
|---|---|---|
| Previous Price * | 119.93 CHF | 29.10.2025 |
| 52 Week High * | 122.80 CHF | 13.02.2025 |
| 52 Week Low * | 102.00 CHF | 09.04.2025 |
| NAV * | 120.17 CHF | 30.10.2025 |
| Issue Price * | ||
| Redemption Price * | ||
| Closing Price * | ||
| Indicative Minimum Price | ||
| Fund Assets *** | 86,213,287 | |
| Unit/Share Assets *** | 44,657,308 | |
| Trading Information SIX | ||
| YTD Performance | +7.84% |
31.12.2024 - 30.10.2025
31.12.2024 30.10.2025 |
|---|---|---|
| 1 month | +1.49% |
30.09.2025 - 30.10.2025
30.09.2025 30.10.2025 |
| 3 months | +0.05% |
30.07.2025 - 30.10.2025
30.07.2025 30.10.2025 |
| 6 months | +5.22% |
30.04.2025 - 30.10.2025
30.04.2025 30.10.2025 |
| 1 year | +6.27% |
30.10.2024 - 30.10.2025
30.10.2024 30.10.2025 |
| 2 years | +32.16% |
30.10.2023 - 30.10.2025
30.10.2023 30.10.2025 |
| 3 years | +34.97% |
31.10.2022 - 30.10.2025
31.10.2022 30.10.2025 |
| 5 years | +23.55% |
14.05.2021 - 30.10.2025
14.05.2021 30.10.2025 |
| Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI Date | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Novartis AG Registered Shares | 6.31% | |
|---|---|---|
| Roche Holding AG | 6.15% | |
| UBS Group AG Registered Shares | 5.25% | |
| Nestle SA | 5.07% | |
| Swiss Re AG | 4.60% | |
| Compagnie Financiere Richemont SA Class A | 4.34% | |
| Zurich Insurance Group AG | 4.28% | |
| Lonza Group Ltd | 3.37% | |
| Givaudan SA | 3.28% | |
| Alcon Inc | 3.13% | |
| Last data update | 31.07.2025 | |
| TER | 1.03% |
|---|---|
| TER date | 30.06.2025 |
| Performance Fee *** | 10.00% |
| PTR | |
| Max. Management Fee *** | 1.00% |
| Ongoing Charges *** | |
|
SRRI ***
|
|
| SRRI date *** | 30.09.2025 |